Abstract
A new class of marine compounds, the didemnins, with potent antitumor activity has been identified. They share the novel structure of a cyclic depsipeptide. Among three structurally related compounds, didemnin B is by far the most potent in its in vitro cytotoxicity and in vivo antitumor activity (0.001 μg/ml inhibits the growth of L1210 leukemia cells by 50%). It also demonstrates good antitumor activity against B16 melanoma and moderate activity against M5076 sarcoma and P388 leukemia. The compound also has good antiviral and potent immunosuppressive properties. Although the precise mechanism of action for the cytotoxicity remains unknown, the agent inhibits protein synthesis more than DNA synthesis and the inhibition of protein synthesis is closely correlated with inhibition of L1210 cell growth. Toxicology studies in CD2F1 mice, Fischer 344 rats and beagle dogs reveal that major target organs are the lymphatics, gastrointestinal tract, liver and kidney. Phase I trials are currently in progress under the auspices of the National Cancer Institute.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rinehart KL Jr, Shaw PD, Shield LS, Gloer JB, Harbour GC, Koker MES, Samain D, Schwartz RE, Tymiak AA, Weller DL, Carter GT, Munro MHG, Hughes RG Jr, Renis HE, Swynenberg EB, Stringfellow DA, Vavra JJ, Coats JH, Zurenko GE, Kuentzel SL, Li LH, Bakus GJ, Brusca RC, Craft LL, Young DN, Connor JL: Marine Natural products as sources of antiviral, antimicrobial and antineoplastic agents. Pure Appl Chem 53:795–817, 1981
Rinehart KL, Gloer JB, Wilson GR, Hughes RG, Li LH, Renis HE, McGovren JP: Antiviral and antitumor compounds from tunicates. Fed Proc 42:87–90, 1983
Rinehart KL, Gloer JB, Hughes RG, Renis HE, McGovren JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: Antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933–935, 1981
Li LH, Renis HE, McGovren JP, Rinehart KL: Didemnins: Novel antitumor and antiviral depsipeptides from the sea (Abstract). Proc Am Assoc Cancer Res 22:255, 1981
Crampton SL, Adams EG, Kuentzel SL, Li LH, Badiner G, Bhuyan BK: Biochemical and cellular effects of Didemnins A and B. Cancer Res 44:1796–1801, 1984
Rinehart KL, Gloer JB, Cook JC, Mizsak SA, Scahill TA: Structures of the Didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc 103:1857–1859, 1981
Montgomery DW, Zukoski CF: Didemnin B: A new immunosuppressive cyclic peptide with potent activity in vitro and in vivo. Transplantation 40:49–56, 1985
Montgomery DW, Kibler R, Poulos B, Zukoski CF, Russell DH: Didemnin B alters the specific binding of prolactin to human lymphocytes and decreases the circulating level of prolactin in mice (Abstract) Fed Proc 44:634, 1985
Li LH, Timmins LG, Wallace TL, Krueger WC, Prairie MD, Im WB: Mechanism of action of Didemnin B, a depsipeptide from the sea. Cancer Lett 23:279–288, 1984
Canonico PG, Pannier WL, Huggins JW, Rinehart KL: Inhibition of RNA viruses in vitro and in Rift Valley Fever-infected mice by Didemnins A and B. Antimicrob Agents Chemother 22:696–697, 1982
Weed SD, Stringfellow DA: Didemnins A and B. Effectiveness against cutaneous herpes simplex virus in mice. Antiviral Res 3:269–274, 1983
Clinical Brochure on Didemnin B (NSC 325319). Prepared by the Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, June 1984
Jiang TL, Liu RH, Salmon SE: Antitumor activity of Didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11:1–4, 1983
Rossof AH, Johnson PA, Kimmell BD, Graham JE, Roseman DL: In vitro Phase II study of Didemnin B in human cancer (Abstract). Proc Am Assoc Cancer Res 24:315, 1983
Page JG, Hubbard ST, Kastello MD, Dodds WJ, Grieshaber CK: Effects of two new antineoplastic agents on blood coagulation (Abstract). Proc Am Assoc Cancer Res 26:369, 1985
Didemnin B: NSC-325319. In: NCI Investigational Drugs: Pharmaceutical Data, NIH Publication No. 85-2141, March 1985, pp 177–178
Stewart JA, Tong WP, Hartshorn JN, McCormack JJ: Phase I evaluation of Didemnin B (NSC 325319) (Abstract). Proc Am Soc Clin Oncol 5:33, 1986
Dorr A, Schwartz R, Kuhn J, Bayne J, Von Hoff DD: Phase I clinical trial of Didemnin B (Abstract). Proc Am Soc Clin Oncol 5:39, 1986
Tucker JB: Drugs from the sea spark renewed interest. Will new anticancer drugs come from marine organisms? Bioscience 35:541–545, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chun, H.G., Davies, B., Hoth, D. et al. Didemnin B. Invest New Drugs 4, 279–284 (1986). https://doi.org/10.1007/BF00179597
Issue Date:
DOI: https://doi.org/10.1007/BF00179597